Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab + Paclitaxel/Carboplatin in Advanced NSCLC
NCT00918203Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2010
- Primary completion
- Aug 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of olaratumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jan 2010; status: completed.
02
Drugs
olaratumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00918203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00918203.